The appointment will involve a time commitment of approximately 22 days per year including 11 meetings. Remuneration for the roles will be at a rate of £325 per meeting.
Similar Posts
Strengthening collaboration between the MHRA and the Department of Health Northern Ireland
The MHRA and Northern Ireland partners are working together to support innovation, enhance patient safety and ensure people in Northern Ireland benefit from world-class regulation.
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
Decision: Advertising Investigations: June 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network
Officers from the MHRA’s Criminal Enforcement Unit (CEU) have raided two separate premises as part of an ongoing investigation into an organised criminal network involved in the manufacture and sale of unlicensed weight loss medicines.
Field Safety Notices: 15 to 19 September 2025
List of Field Safety Notices from 15 to 19 September 2025.